Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Lowered by StockNews.com

Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

A number of other brokerages also recently commented on KPTI. Royal Bank of Canada reduced their target price on shares of Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating on the stock in a research note on Tuesday. Robert W. Baird dropped their price objective on shares of Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating for the company in a report on Tuesday. HC Wainwright boosted their price target on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a report on Wednesday, February 26th. Finally, Barclays boosted their price target on shares of Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.20.

Karyopharm Therapeutics Price Performance

Shares of KPTI stock opened at $5.44 on Wednesday. The firm’s 50-day moving average is $5.41 and its two-hundred day moving average is $8.79. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $17.85. The company has a market capitalization of $46.62 million, a PE ratio of -5.33 and a beta of 0.33.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Monday, May 12th. The company reported ($2.77) EPS for the quarter, topping analysts’ consensus estimates of ($4.21) by $1.44. The firm had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $35.12 million. Sell-side analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors have recently modified their holdings of KPTI. Velan Capital Investment Management LP purchased a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $27,000. Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at $31,000. TD Waterhouse Canada Inc. purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at $32,000. Two Sigma Advisers LP raised its position in Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP purchased a new stake in Karyopharm Therapeutics in the 4th quarter valued at $85,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).